Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Medtronic
Mallinckrodt
Moodys
Boehringer Ingelheim

Last Updated: January 31, 2023

Details for Patent: 7,378,423


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 7,378,423 protect, and when does it expire?

Patent 7,378,423 protects MEKINIST and is included in one NDA.

This patent has forty-nine patent family members in twenty-eight countries.

Summary for Patent: 7,378,423
Title:Pyrimidine compound and medical use thereof
Abstract: The present invention relates to a pyrimidine compound or a pharmaceutically acceptable salt thereof represented by the following formula [I] ##STR00001## wherein each symbol is as defined in the specification and a method of therapeutically or prophylactically treating an undesirable cell proliferation, comprising administering such a compound. The compound of the present invention has superior activity in suppressing undesirable cell proliferation, particularly, an antitumor activity, and is useful as an antitumor agent for the prophylaxis or treatment of cancer, rheumatism, and the like. In addition, the compound of the present invention can be a more effective antitumor agent when used in combination with other antitumor agents such as an alkylating agent or metabolism antagonist.
Inventor(s): Kawasaki; Hisashi (Osaka, JP), Abe; Hiroyuki (Osaka, JP), Hayakawa; Kazuhide (Osaka, JP), Iida; Tetsuya (Osaka, JP), Kikuchi; Shinichi (Osaka, JP), Yamaguchi; Takayuki (Osaka, JP), Nanayama; Toyomichi (Osaka, JP), Kurachi; Hironori (Osaka, JP), Tamaru; Masahiro (Osaka, JP), Hori; Yoshikazu (Osaka, JP), Takahashi; Mitsuru (Osaka, JP), Yoshida; Takayuki (Yokohama, JP), Sakai; Toshiyuki (Kyoto, JP)
Assignee: Japan Tobacco Inc. (Tokyo, JP)
Application Number:11/150,792
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,378,423

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-001 May 29, 2013 RX Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-002 May 29, 2013 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novartis MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-003 May 29, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,378,423

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2004-174770Jun 11, 2004
Japan2004-327111Nov 10, 2004

International Family Members for US Patent 7,378,423

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 383360 See Plans and Pricing
Australia 2005252110 See Plans and Pricing
Brazil PI0511967 See Plans and Pricing
Canada 2569850 See Plans and Pricing
Canada 2727841 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
Mallinckrodt
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.